STOCK TITAN

[SCHEDULE 13G] Performant Healthcare, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Glazer Capital, LLC and its managing member Paul J. Glazer filed a Schedule 13G reporting shared voting and dispositive power over 2,474,820 shares of scPharmaceuticals Inc. common stock, representing 4.64% of the class. The filing states the shares are held by funds and managed accounts for which Glazer Capital is investment manager and that the position is not held to influence control of the issuer. The reporting persons provide their business address in New York and identify Glazer Capital as a Delaware LLC and Paul J. Glazer as a U.S. citizen. The filing notes that the reporting persons previously may have been deemed to own more than 5% but have ceased to be beneficial owners of more than five percent as of the date of this statement.

Glazer Capital, LLC e il suo membro amministratore Paul J. Glazer hanno depositato un Schedule 13G dichiarando il possesso congiunto del diritto di voto e dispositivi su 2.474.820 azioni ordinarie di scPharmaceuticals Inc., corrispondenti al 4,64% della classe. La dichiarazione precisa che le azioni sono detenute da fondi e conti gestiti per i quali Glazer Capital svolge il ruolo di gestore degli investimenti e che la posizione non è detenuta con l’intento di influenzare il controllo dell’emittente. I soggetti che presentano la segnalazione indicano il loro indirizzo commerciale a New York, identificano Glazer Capital come LLC del Delaware e Paul J. Glazer come cittadino statunitense. Il documento segnala inoltre che in passato i soggetti potrebbero essere stati considerati proprietari di oltre il 5%, ma che alla data della presente comunicazione non sono più beneficiari di oltre il cinque percento.

Glazer Capital, LLC y su miembro gestor Paul J. Glazer presentaron un Schedule 13G en el que informan de poderes compartidos de voto y disposición sobre 2.474.820 acciones ordinarias de scPharmaceuticals Inc., que representan el 4,64% de la clase. La presentación indica que las acciones están en fondos y cuentas gestionadas para las que Glazer Capital actúa como gestor de inversiones y que la posición no se mantiene con el fin de influir en el control del emisor. Los declarante facilitan su dirección comercial en Nueva York e identifican a Glazer Capital como una LLC de Delaware y a Paul J. Glazer como ciudadano estadounidense. El documento señala además que, anteriormente, los informantes pudieron haber sido considerados propietarios de más del 5%, pero han dejado de ser beneficiarios de más del cinco por ciento a la fecha de esta declaración.

Glazer Capital, LLC와 그 관리 구성원 Paul J. Glazer는 공동 의결권 및 처분권을 보고하는 Schedule 13G를 제출하여 scPharmaceuticals Inc.의 보통주 2,474,820주, 즉 해당 종류의 4.64%를 보유하고 있다고 밝혔습니다. 서류에는 해당 주식이 Glazer Capital이 투자 관리자 역할을 하는 펀드 및 관리 계좌에 보관되어 있으며, 발행회사의 지배에 영향을 미치기 위한 목적은 아니라고 명시되어 있습니다. 보고인들은 뉴욕에 사업 주소를 기재하고 Glazer Capital을 델라웨어 LLC로, Paul J. Glazer를 미국 시민으로 식별했습니다. 또한 보고서에는 과거에 보고인들이 5%를 초과하여 보유한 것으로 간주되었을 수 있으나 이 진술서 날짜 기준으로는 5%를 초과하는 실질적 보유자가 아니게 되었다고 기재되어 있습니다.

Glazer Capital, LLC et son membre dirigeant Paul J. Glazer ont déposé un Schedule 13G déclarant des pouvoirs partagés de vote et de disposition sur 2 474 820 actions ordinaires de scPharmaceuticals Inc., soit 4,64 % de la catégorie. Le dépôt précise que les actions sont détenues par des fonds et des comptes gérés pour lesquels Glazer Capital est gestionnaire d'investissement et que la position n'est pas détenue dans le but d'influencer le contrôle de l'émetteur. Les personnes déclarantes fournissent leur adresse professionnelle à New York et identifient Glazer Capital comme une LLC du Delaware et Paul J. Glazer comme ressortissant américain. Le document indique en outre que ces déclarants ont peut-être été considérés auparavant comme détenteurs de plus de 5 %, mais qu'ils ont cessé d'être des propriétaires bénéficiaires de plus de cinq pour cent à la date de cette déclaration.

Glazer Capital, LLC und dessen geschäftsführendes Mitglied Paul J. Glazer haben ein Schedule 13G eingereicht, in dem sie gemeinschaftliche Stimm- und Verfügungsrechte an 2.474.820 Stammaktien der scPharmaceuticals Inc. melden, was 4,64% der Klasse entspricht. In der Einreichung wird angegeben, dass die Aktien von Fonds und verwalteten Konten gehalten werden, für die Glazer Capital als Investmentmanager fungiert, und dass die Position nicht dazu dient, die Kontrolle über den Emittenten zu beeinflussen. Die meldenden Personen geben ihre Geschäftsadresse in New York an und identifizieren Glazer Capital als eine Delaware LLC sowie Paul J. Glazer als US-Staatsbürger. Außerdem wird vermerkt, dass die meldenden Personen früher möglicherweise als Inhaber von mehr als 5% galten, zum Zeitpunkt dieser Erklärung jedoch nicht mehr als wirtschaftliche Eigentümer von über fünf Prozent gelten.

Positive
  • Transparent disclosure of ownership: reporting of 2,474,820 shares (4.64%) provides clarity to the market
  • Passive position affirmed: filing states shares are not held to influence or change issuer control
Negative
  • None.

Insights

TL;DR: Passive disclosure: a 4.64% shared stake reported, consistent with an investment-adviser filing under Schedule 13G.

The Schedule 13G shows Glazer Capital serves as investment manager to funds and managed accounts holding 2,474,820 shares of scPharmaceuticals Inc., with shared voting and dispositive power but no sole voting or dispositive power. Classification codes (IA, OO for the entity; IN for the individual) indicate an investment adviser filing and an individual investor disclosure. The filing explicitly states the position is not intended to change or influence issuer control, which aligns with passive investor treatment under Rule 13d-1. The note that the reporting persons "ceased to be the beneficial owner of more than five percent" is administratively important because it affects filing status and market signaling about position sizing.

TL;DR: Governance implications are limited: shared voting power exists, but the filing affirms a non-control, passive stake.

The document discloses shared voting and dispositive power for 2,474,820 shares but explicitly denies intent to influence control, reducing immediate governance concerns. Because no sole voting or dispositive power is reported, the filing does not indicate an attempt to direct board or strategic change. The prior reference to having been over 5% and then falling below that threshold is noteworthy for governance monitoring because crossing those thresholds can trigger changes in disclosure obligations and market perception, yet current ownership remains below the 5% materiality threshold.

Glazer Capital, LLC e il suo membro amministratore Paul J. Glazer hanno depositato un Schedule 13G dichiarando il possesso congiunto del diritto di voto e dispositivi su 2.474.820 azioni ordinarie di scPharmaceuticals Inc., corrispondenti al 4,64% della classe. La dichiarazione precisa che le azioni sono detenute da fondi e conti gestiti per i quali Glazer Capital svolge il ruolo di gestore degli investimenti e che la posizione non è detenuta con l’intento di influenzare il controllo dell’emittente. I soggetti che presentano la segnalazione indicano il loro indirizzo commerciale a New York, identificano Glazer Capital come LLC del Delaware e Paul J. Glazer come cittadino statunitense. Il documento segnala inoltre che in passato i soggetti potrebbero essere stati considerati proprietari di oltre il 5%, ma che alla data della presente comunicazione non sono più beneficiari di oltre il cinque percento.

Glazer Capital, LLC y su miembro gestor Paul J. Glazer presentaron un Schedule 13G en el que informan de poderes compartidos de voto y disposición sobre 2.474.820 acciones ordinarias de scPharmaceuticals Inc., que representan el 4,64% de la clase. La presentación indica que las acciones están en fondos y cuentas gestionadas para las que Glazer Capital actúa como gestor de inversiones y que la posición no se mantiene con el fin de influir en el control del emisor. Los declarante facilitan su dirección comercial en Nueva York e identifican a Glazer Capital como una LLC de Delaware y a Paul J. Glazer como ciudadano estadounidense. El documento señala además que, anteriormente, los informantes pudieron haber sido considerados propietarios de más del 5%, pero han dejado de ser beneficiarios de más del cinco por ciento a la fecha de esta declaración.

Glazer Capital, LLC와 그 관리 구성원 Paul J. Glazer는 공동 의결권 및 처분권을 보고하는 Schedule 13G를 제출하여 scPharmaceuticals Inc.의 보통주 2,474,820주, 즉 해당 종류의 4.64%를 보유하고 있다고 밝혔습니다. 서류에는 해당 주식이 Glazer Capital이 투자 관리자 역할을 하는 펀드 및 관리 계좌에 보관되어 있으며, 발행회사의 지배에 영향을 미치기 위한 목적은 아니라고 명시되어 있습니다. 보고인들은 뉴욕에 사업 주소를 기재하고 Glazer Capital을 델라웨어 LLC로, Paul J. Glazer를 미국 시민으로 식별했습니다. 또한 보고서에는 과거에 보고인들이 5%를 초과하여 보유한 것으로 간주되었을 수 있으나 이 진술서 날짜 기준으로는 5%를 초과하는 실질적 보유자가 아니게 되었다고 기재되어 있습니다.

Glazer Capital, LLC et son membre dirigeant Paul J. Glazer ont déposé un Schedule 13G déclarant des pouvoirs partagés de vote et de disposition sur 2 474 820 actions ordinaires de scPharmaceuticals Inc., soit 4,64 % de la catégorie. Le dépôt précise que les actions sont détenues par des fonds et des comptes gérés pour lesquels Glazer Capital est gestionnaire d'investissement et que la position n'est pas détenue dans le but d'influencer le contrôle de l'émetteur. Les personnes déclarantes fournissent leur adresse professionnelle à New York et identifient Glazer Capital comme une LLC du Delaware et Paul J. Glazer comme ressortissant américain. Le document indique en outre que ces déclarants ont peut-être été considérés auparavant comme détenteurs de plus de 5 %, mais qu'ils ont cessé d'être des propriétaires bénéficiaires de plus de cinq pour cent à la date de cette déclaration.

Glazer Capital, LLC und dessen geschäftsführendes Mitglied Paul J. Glazer haben ein Schedule 13G eingereicht, in dem sie gemeinschaftliche Stimm- und Verfügungsrechte an 2.474.820 Stammaktien der scPharmaceuticals Inc. melden, was 4,64% der Klasse entspricht. In der Einreichung wird angegeben, dass die Aktien von Fonds und verwalteten Konten gehalten werden, für die Glazer Capital als Investmentmanager fungiert, und dass die Position nicht dazu dient, die Kontrolle über den Emittenten zu beeinflussen. Die meldenden Personen geben ihre Geschäftsadresse in New York an und identifizieren Glazer Capital als eine Delaware LLC sowie Paul J. Glazer als US-Staatsbürger. Außerdem wird vermerkt, dass die meldenden Personen früher möglicherweise als Inhaber von mehr als 5% galten, zum Zeitpunkt dieser Erklärung jedoch nicht mehr als wirtschaftliche Eigentümer von über fünf Prozent gelten.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Glazer Capital, LLC
Signature:Paul J. Glazer
Name/Title:Paul J. Glazer, Managing Member
Date:09/09/2025
Paul J. Glazer
Signature:Paul J. Glazer
Name/Title:Paul J. Glazer
Date:09/09/2025

FAQ

What stake in scPharmaceuticals Inc. (symbol provided) do Glazer Capital and Paul J. Glazer report?

They report shared voting and dispositive power over 2,474,820 shares, representing 4.64% of the class.

Is the position reported as an attempt to influence control of the issuer?

No; the filing certifies the securities were not acquired and are not held for the purpose of changing or influencing control.

Who holds the shares on behalf of Glazer Capital?

The shares are held by certain funds and managed accounts for which Glazer Capital acts as investment manager (collectively, the Glazer Funds).

Do the reporting persons claim sole voting or dispositive power over the shares?

No; the filing reports 0 shares with sole voting or dispositive power and 2,474,820 shares with shared voting and dispositive power.

Has Glazer Capital ever exceeded 5% ownership of the class?

The filing states the reporting persons "may have been deemed to beneficially own more than 5%" on the event date but that they have ceased to be beneficial owners of more than five percent as of the filing date.
Performant Finl Corp

NASDAQ:PHLT

PHLT Rankings

PHLT Latest News

PHLT Latest SEC Filings

PHLT Stock Data

604.33M
69.74M
8.16%
92.51%
11.43%
Health Information Services
Services-miscellaneous Business Services
Link
United States
PLANTATION